The article discusses the principles behind inheritance laws that prevent those who commit wrongful acts, like murder, from profiting from their actions. It draws parallels to Purdue Pharma's situation, as the company seeks to defend patents on opioid formulations while confronting its role in the opioid epidemic. Purdue plans to restructure as a public benefit company by 2025, a legal and ethical transformation intended to rectify its prior damages. This complex reorganization unfolds within a court-supervised bankruptcy, raising questions about corporate responsibility and redemption similar to historical biblical transformations.
In virtually all jurisdictions, the common law principle "no one shall profit from their own wrong" prevents murderers from inheriting from their victims, known as the slayer rule.
Purdue Pharma's recent Supreme Court filing presents an ethical dilemma of whether wrongdoers should profit from their own misconduct, particularly regarding the opioid crisis.
Purdue Pharma's plan to become a public benefit company by 2025 signifies a complex transformation, akin to a death and rebirth, aimed at addressing the opioid crisis.
The company faces a court-supervised bankruptcy proceeding, with the potential to change its mission through negotiated legal remedies rather than a moral conversion.
Collection
[
|
...
]